E. Dotor

668 total citations
23 papers, 462 citations indexed

About

E. Dotor is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, E. Dotor has authored 23 papers receiving a total of 462 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in E. Dotor's work include Colorectal Cancer Treatments and Studies (11 papers), Gastric Cancer Management and Outcomes (6 papers) and Colorectal Cancer Surgical Treatments (5 papers). E. Dotor is often cited by papers focused on Colorectal Cancer Treatments and Studies (11 papers), Gastric Cancer Management and Outcomes (6 papers) and Colorectal Cancer Surgical Treatments (5 papers). E. Dotor collaborates with scholars based in Spain, France and United Kingdom. E. Dotor's co-authors include Carles Pericay, Eugeni Saigí, Álex Casalots, Xavier Serra‐Aracil, Anna Ruiz, Matilde Navarro, Anna Ferrer, Enrique Aranda, Fernando Rivera and Josep R. Germà and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and European Journal of Cancer.

In The Last Decade

E. Dotor

23 papers receiving 457 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Dotor Spain 10 270 173 154 96 70 23 462
Anna Maria Elisabeth Walenkamp Netherlands 9 271 1.0× 117 0.7× 73 0.5× 79 0.8× 68 1.0× 17 467
Kota Ouchi Japan 12 251 0.9× 164 0.9× 163 1.1× 72 0.8× 110 1.6× 42 503
Johanna Wassermann France 12 197 0.7× 77 0.4× 98 0.6× 57 0.6× 83 1.2× 41 514
J McKendrick Australia 9 338 1.3× 121 0.7× 59 0.4× 81 0.8× 180 2.6× 24 525
Fernando Gaion Italy 8 411 1.5× 199 1.2× 48 0.3× 74 0.8× 143 2.0× 11 541
Won Jin Chang South Korea 12 177 0.7× 79 0.5× 91 0.6× 30 0.3× 110 1.6× 27 353
Shinichi Asaka Japan 12 161 0.6× 175 1.0× 96 0.6× 109 1.1× 111 1.6× 58 462
Sugganth Daniel United States 7 196 0.7× 62 0.4× 70 0.5× 46 0.5× 96 1.4× 26 313
David Rossi Italy 12 179 0.7× 76 0.4× 78 0.5× 73 0.8× 108 1.5× 20 593
Tanja K. Froehlich Switzerland 8 341 1.3× 187 1.1× 59 0.4× 24 0.3× 76 1.1× 11 475

Countries citing papers authored by E. Dotor

Since Specialization
Citations

This map shows the geographic impact of E. Dotor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Dotor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Dotor more than expected).

Fields of papers citing papers by E. Dotor

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Dotor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Dotor. The network helps show where E. Dotor may publish in the future.

Co-authorship network of co-authors of E. Dotor

This figure shows the co-authorship network connecting the top 25 collaborators of E. Dotor. A scholar is included among the top collaborators of E. Dotor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Dotor. E. Dotor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Capdevila, Jaume, Àlex Teulé, Jorge Barriuso, et al.. (2018). Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study. The Oncologist. 24(1). 38–46. 22 indexed citations
3.
Vera, Ruth, E. Dotor, Jaime Feliú, et al.. (2016). SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). Clinical & Translational Oncology. 18(12). 1172–1178. 24 indexed citations
4.
Pericay, Carles, Ferrán Losa, Luis Cirera, et al.. (2016). Phase II study with docetaxel (D), cisplatin (C) and continuous capecitabine (X) schedule (DCX) in advanced gastric cancer (AGC): ML21085. Final results.. Journal of Clinical Oncology. 34(15_suppl). e15520–e15520. 1 indexed citations
5.
Blanco, Remei, et al.. (2016). Multidisciplinary treatment planning in elderly patients with cancer: a prospective observational study. The Journal of Community and Supportive Oncology. 14(11). 466–472. 5 indexed citations
6.
7.
8.
Pericay, Carles, et al.. (2015). Further evidence for preoperative chemoradiotherapy and transanal endoscopic surgery (TEM) in T2-3s,N0,M0 rectal cancer. Clinical & Translational Oncology. 18(7). 666–671. 9 indexed citations
9.
10.
Casanovas, Oriol, Jaume Capdevila, Jorge Barriuso, et al.. (2014). Potential role of mTOR phosphorylation status as a negative predictor to everolimus plus octreotide in NETs.. Journal of Clinical Oncology. 32(3_suppl). 484–484. 1 indexed citations
11.
Grande, Enrique, Carmen Guillén‐Ponce, Margarita Reboredo, et al.. (2014). Regorafenib as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC): A study of the Spanish Cooperative Group for digestive tumor therapy (TTD).. Journal of Clinical Oncology. 32(15_suppl). TPS3651–TPS3651. 3 indexed citations
12.
Borràs, Emma, E. Dotor, Àngels Arcusa, et al.. (2013). High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity. Frontiers in Genetics. 3. 312–312. 10 indexed citations
13.
Pericay, Carles, Anna Ferrer, E. Dotor, et al.. (2013). microRNA expression profile in stage III colorectal cancer: Circulating miR-18a and miR-29a as promising biomarkers. Oncology Reports. 30(1). 320–326. 142 indexed citations
14.
Pericay, Carles, et al.. (2011). Role of chemoradiotherapy alone in the management of unfit patients with nonmetastatic locally advanced squamous cell carcinoma of the esophagus.. Journal of Clinical Oncology. 29(4_suppl). 138–138. 2 indexed citations
15.
Pericay, Carles, et al.. (2009). Extravasation of oxaliplatin: an infrequent and irritant toxicity. Clinical & Translational Oncology. 11(2). 114–116. 10 indexed citations
16.
Blanco, R., et al.. (2009). P7 Multidisciplinary assessment in elderly oncologic patients for treatment planning: final results of a prospective observational study in a General Hospital. Critical Reviews in Oncology/Hematology. 72(1). S21–S21. 1 indexed citations
17.
Majem, Margarita, Maica Galán, Montserrat Muñoz-Mateu, et al.. (2007). The oncology acute toxicity unit (OATU): an outpatient facility for improving the management of chemotherapy toxicity. Clinical & Translational Oncology. 9(12). 784–788. 20 indexed citations
18.
Navarro, Matilde, E. Dotor, Fernando Rivera, et al.. (2006). A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. International Journal of Radiation Oncology*Biology*Physics. 66(1). 201–205. 54 indexed citations
19.
Dotor, E., Maria E. Vega, Pedro Sánchez‐Rovira, et al.. (2004). Irinotecan (CPT-11) and 5-fluorouracil (5-FU) concomitantly with preoperative radiotherapy (RT) in patients (pts) with locally advanced resectable rectal cancer. Updated results of a phase II study. Journal of Clinical Oncology. 22(14_suppl). 4179–4179. 1 indexed citations
20.
Dotor, E., Matilde Navarro, Maria E. Vega, et al.. (2004). Irinotecan (CPT-11) and 5-fluorouracil (5-FU) concomitantly with preoperative radiotherapy (RT) in patients (pts) with locally advanced resectable rectal cancer. Updated results of a phase II study. Journal of Clinical Oncology. 22(14_suppl). 4179–4179. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Maria Elisabeth Walenkamp Breakdown of academic impact, for papers by Kota Ouchi Breakdown of academic impact, for papers by Johanna Wassermann Breakdown of academic impact, for papers by J McKendrick Breakdown of academic impact, for papers by Fernando Gaion Breakdown of academic impact, for papers by Won Jin Chang Breakdown of academic impact, for papers by Shinichi Asaka Breakdown of academic impact, for papers by Sugganth Daniel Breakdown of academic impact, for papers by David Rossi Breakdown of academic impact, for papers by Tanja K. Froehlich
Rankless by CCL
2026